- Home
- BBIO vs CHH Comparison
BBIO vs CHH Comparison
Compare BBIO & CHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- CHH
- Stock Information
- Founded
- BBIO 2015
- CHH 1939
- Country
- BBIO United States
- CHH United States
- Employees
- BBIO N/A
- CHH N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- CHH Hotels/Resorts
- Sector
- BBIO Health Care
- CHH Consumer Discretionary
- Exchange
- BBIO Nasdaq
- CHH Nasdaq
- Market Cap
- BBIO 6.7B
- CHH 5.8B
- IPO Year
- BBIO 2019
- CHH 1997
- Fundamental
- Price
- BBIO $34.25
- CHH $126.71
- Analyst Decision
- BBIO Strong Buy
- CHH Hold
- Analyst Count
- BBIO 12
- CHH 14
- Target Price
- BBIO $57.09
- CHH $133.64
- AVG Volume (30 Days)
- BBIO 2.9M
- CHH 468.6K
- Earning Date
- BBIO 04-29-2025
- CHH 05-08-2025
- Dividend Yield
- BBIO N/A
- CHH 0.91%
- EPS Growth
- BBIO N/A
- CHH 40.19
- EPS
- BBIO N/A
- CHH 6.57
- Revenue
- BBIO $127,415,000.00
- CHH $797,663,000.00
- Revenue This Year
- BBIO $89.10
- CHH $101.22
- Revenue Next Year
- BBIO $57.07
- CHH $3.71
- P/E Ratio
- BBIO N/A
- CHH $19.29
- Revenue Growth
- BBIO N/A
- CHH N/A
- 52 Week Low
- BBIO $21.62
- CHH $109.46
- 52 Week High
- BBIO $39.54
- CHH $157.86
- Technical
- Relative Strength Index (RSI)
- BBIO 50.58
- CHH 47.24
- Support Level
- BBIO $31.77
- CHH $126.52
- Resistance Level
- BBIO $33.93
- CHH $130.96
- Average True Range (ATR)
- BBIO 1.28
- CHH 2.89
- MACD
- BBIO -0.09
- CHH -0.00
- Stochastic Oscillator
- BBIO 57.14
- CHH 30.60
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About CHH Choice Hotels International Inc.
As of Dec. 31, 2024, Choice Hotels operated 654,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (26% of the company's total domestic rooms), while Ascend and Cambria (10% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represent 78% of total rooms in 2024.